Oxurion Publishes First Half 2022 Results
September 07, 2022 02:25 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – September 7, 2022 – 8.00 am CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies,...
Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in Funding
September 02, 2022 17:00 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – September 2, 2022 – CET 10:30PM – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies,...
Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op NEGMA Conversie-Notificatie
August 26, 2022 13:00 ET
|
Oxurion NV
Negma Group heeft 200 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 500.000. Deze conversie vormt deel van Negma Group’s EUR 30 miljoen...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
August 26, 2022 13:00 ET
|
Oxurion NV
Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to...
Oxurion To Present at Upcoming Scientific and Investor Conferences
August 24, 2022 13:00 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – August 24, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical...
Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op NEGMA Conversie-Notificatie
July 29, 2022 13:00 ET
|
Oxurion NV
Negma Group heeft 220 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 550.000. Deze conversie vormt deel van Negma Group’s EUR 30 miljoen...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
July 29, 2022 13:00 ET
|
Oxurion NV
Negma Group has converted 220 convertible bonds in Oxurion resulting in a EUR 550,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to...
Oxurion Announces Presentations at Upcoming Scientific and Investor Conferences
July 11, 2022 13:00 ET
|
Oxurion NV
Leuven, BELGIUM, Boston, MA, US – July 11, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage...
Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend conversie van Negma Converteerbare Obligaties en Gedeeltelijke Terugbetaling van Kreos/Pontifax Converteerbare Obligaties
June 30, 2022 14:00 ET
|
Oxurion NV
Negma Group heeft 180 converteerbare obligaties geconverteerd resulterende in een kapitaalverhoging van EUR 450.000 en Kreos/Pontifax converteerbare obligaties werden terugbetaald ten belope van een...
Information on the Total Number of Voting Rights (Denominator) following Conversion of Negma Convertible Bonds and Partial Reimbursement of Kreos/Pontifax Convertible Bonds
June 30, 2022 14:00 ET
|
Oxurion NV
Negma Group has converted 180 convertible bonds resulting in a EUR 450,000 capital increase and Kreos/Pontifax convertible bonds have been reimbursed in an amount of EUR 3 million Leuven, BELGIUM,...